Insulin therapy in type 2 diabetes
95 results
1 - 95
Insulin therapy in type 2 diabetes 
Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control- Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus
- Insulin added on metformin in type 2 diabetes
- Diabetes: definition, differential diagnosis and classification
- Comprehensive treatment and follow-up of type 2 diabetes
- Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus: Cochrane systematic review
- Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin
- A child or adolescent with type 1 diabetes in primary health care
- Incretin-based therapy with dipeptidyl peptidase 4 inhibitors in type 2 diabetes
SGLT2 inhibitors, GLP1 agonists provide greater benefit for patients with type 2 diabetes- (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus
- Basal insulin less effective, better tolerated than biphasic and prandial
- Sulphonylurea monotherapy for patients with type 2 diabetes mellitus: Cochrane systematic review
- Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis
- Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
- Fracture risk based on BMD and FRAX score higher in adults with type 2 diabetes
- Enhanced glucose control for preventing and treating diabetic neuropathy
- Insulin for the treatment of women with gestational diabetes
- Risk of severe hypoglycemia similar between different insulin formulations
- Oral antidiabetic drugs and GLP-1 analogues
- Pioglitazone for type 2 diabetes mellitus
- Continuous glucose monitoring systems for type 1 diabetes mellitus
- Similar long-term morbidity and mortality with human insulin and analogue insulins
- Rosiglitazone for type 2 diabetes mellitus
- Continuous glucose monitoring systems for type 1 diabetes mellitus
- Little benefit to revascularization over intensive medical treatment in DM with CAD
- Closed-loop system improves glycemic control but not hypoglycemia for young children with type 1 diabetes mellitus
- Sliding scale insulin for non‐critically ill hospitalised adults with diabetes mellitus
- Moderately intensive control of T2DM improves clinical outcomes (UKPDS)
- Inhaled insulin in diabetes mellitus: Cochrane systematic review
- Intensive glucose therapy during hospitalization for stroke does not improve functional outcomes (SHINE)
- For post-thrombolysis hyperglycemia: no reduction in symptomatic intracerebral hemorrhage with continuous intravenous insulin therapy
- NPH insulin: fewer episodes of severe hypoglycemia than analogs (Lantus and Levemir) and less than half the cost
- Insulin versus oral anti-diabetic pharmacological therapies for gestational diabetes
- Interventions for latent autoimmune diabetes (LADA) in adults: Cochrane systematic review
- Continuous glucose monitoring adds little benefit, especially in adults
- Gestational diabetes mellitus (GDM)
- Definition and diagnosis of dyslipidaemias
- Type 2 diabetes: metformin first, other treatments second
- Diabetic kidney disease (diabetic nephropathy)
- The use of glitazones (thiazolidinediones) in heart failure
- Exercise for diabetic pregnant women
- Colesevelam for type 2 diabetes mellitus
- Glucagon-like peptide analogues (GLP-1 analogues) for type 2 diabetes
- J-shaped survival curve for glycemic control in patients with type 2 DM
- Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews
- Type 1 diabetes: treatment
- Dietary supplementation with myo‐inositol in women during pregnancy for treating gestational diabetes
- Weekly tirzepatide + metformin better than daily insulin degludec + metformin in decreasing A1C, weight, and hypoglycemia (SURPASS-3)
- Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease
- Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes
- Chronic diseases and pregnancy
- Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
- Glargine and liraglutide are the best second drugs after metformin for achieving tight glycemic control (in a study without SGLT2 inhibitors)
- Different intensities of glycaemic control for women with gestational diabetes mellitus
- Intensive control of glucose does not improve T2DM outcomes (VADT)
- Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome
- Choice of antihypertensive drug in the diabetic patient from prognostic point of view
- Risk of lactic acidosis with metformin in type 2 diabetes
- Intensive weight management for remission of type 2 diabetes
- Adding dulaglutide only slightly decreases major adverse CV events in patients with T2DM and CVD risk factors (REWIND)
- Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
- Liraglutide probably the best second drug to prevent cardiovascular events in patients with T2DM who take metformin
- Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes
- Treatment of chronic renal failure
- Rare endocrine tumours
- Fetal biometry for guiding the medical management of women with gestational diabetes mellitus for improving maternal and perinatal health
- Polycystic ovary syndrome (PCOS)
- Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes
- Conservative (non-surgical) treatment of obesity
- Chronic heart failure